ESMO: BMS’s Opdivo Edges Merck & Co’s Keytruda In First-Line Advanced Gastroesophageal Cancers
Competition Will Be Fierce Between Checkpoint Inhibitors
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
You may also be interested in...
Accounting for nearly a third of the global clinical pipeline, the oncology sector is set to grow to $250bn in sales by 2024 predicts a new report, identifying five research trends driving broad changes. COVID-19 has impacted trials, with 2% having been slowed down, suspended or discontinued.
Merck & Co is working hard to extend the indications for Keytruda, and reports the checkpoint inhibitor significantly improves overall survival and PFS when combined with chemotherapy in the first-line treatment of metastatic esophageal cancer.
Results presented as ASCO from the mixed KEYNOTE-062 study suggest a place for pembrolizumab in first-line gastric cancer but data from other ongoing trials will be needed to support filings amid looming competition from Opdivo.